引用本文:林 萌,陈贤娥.金双歧联合美沙拉嗪治疗儿童活动期炎症性肠病临床疗效分析[J].中国临床新医学,2018,11(12):1246-1249.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 56次   下载 33 本文二维码信息
码上扫一扫!
分享到: 微信 更多
金双歧联合美沙拉嗪治疗儿童活动期炎症性肠病临床疗效分析
林 萌,陈贤娥
350001 福州,福建医科大学省立临床医学院、福建省立医院儿科
摘要:
[摘要] 目的 探讨金双歧联合美沙拉嗪治疗儿童活动期炎症性肠病(IBD)的临床效果。方法 将40例确诊为活动期IBD的患儿分为两组,每组20例。对照组服用美沙拉嗪治疗,观察组服用金双歧和美沙拉嗪联合治疗。均持续治疗2个月,对比两组患者肠道菌群分布、血清C反应蛋白(CRP)、血沉(ESR)、白介素-23(IL-23)表达及Th17细胞水平,统计两组临床疗效及不良反应发生情况。结果 对照组治疗后肠道大肠杆菌、双歧杆菌、乳酸杆菌及肠球菌数量均明显变化。观察组治疗后双歧杆菌、乳酸杆菌数量明显增加,肠球菌数量明显减少(P<0.05)。两组治疗后血清中CRP、ESR、IL-23水平及Th17细胞水平均明显下降,且观察组明显低于对照组(P<0.05)。观察组显效10例,有效9例,效1例。对照组显效5例,有效8例,效7例。观察组疗效优于对照组(P<0.05)。观察组不良反应发生率仅为5%,明显优于对照组的35%(P<0.05)。结论 金双歧联合美沙拉嗪在儿童活动期IBD治疗中效果显著,可有效抑制炎症反应,恢复肠道微生态平衡,调节免疫功能,减少美沙拉嗪的胃肠道副作用,提高临床疗效,安全性高。
关键词:  炎症性肠病  活动期  儿童  金双歧  美沙拉嗪  疗效
DOI:10.3969/j.issn.1674-3806.2018.12.20
分类号:R 57
基金项目:
Clinical efficacy of Golden Bifidobacterium combined with mesalazine in treatment of children with active inflammatory bowel disease
LIN Meng, CHEN Xian-e
Provincial Institute of Clinical Medicine, Fujian Medical University,Department of Pediatrics of Fujian Provincial Hospital, Fuzhou 350001, China
Abstract:
[Abstract] Objective To explore the clinical effect of Golden Bifidobacterium combined with mesalazine in treatment of children with active inflammatory bowel disease(IBD). Methods Forty children with active IBD were divided into two groups, with 20 cases in each group. The control group was treated with mesalazine, and the observation group received Golden Bifidobacterium and mesalazine. The distribution of intestinal flora, the expressions of serum CRP, ESR and IL-23 and the levels of Th17 cells were compared between the two groups, and the clinical efficacy and adverse reactions were statistically analyzed in the two groups 2 months after the continuous treatment. Results Compared with those after treatment, the numbers of intestinal escherichia coli, bifidobacteria, lactobacillus and enterococcus in the control group were not significantly changed, but the numbers of bifidobacteria and lactobacillus in the observation group were significantly increased and the number of enterococcus was significantly decreased(P<0.05). The levels of CRP, ESR, IL-23 and Th17 cells in the two groups were significantly decreased and those of the observation group were significantly lower than those of the control group(P<0.05). In the observation group, 10 cases were markedly effective, 9 cases effective, and 1 case ineffective. In the control group, 5 cases were markedly effective, 8 cases effective, and 7 cases ineffective. The clinical effect of the observation group was better than that of the control group(P<0.05). The incidence of adverse reactions in the observation group(5%) was significantly lower than that in the control group(35%)(P<0.05). Conclusion The clinical effect of Golden Bifidobacterium combined with mesalazine is significantly effective in treatment of children with active inflammatory bowel disease. It can effectively inhibit the inflammatory reaction, restore the intestinal microecological balance, regulate the immune function, reduce the side effects of the gastrointestinal tract of mesalazine, and improve the clinical efficacy.
Key words:  Inflammatory bowel disease  Activity  Children  Golden Bifidobacterium  Mesalazine  Curative effect